Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00228-013-1620-7 | DOI Listing |
J Neuroimmune Pharmacol
March 2017
Department of Neurology, University Hospital Cologne, Cologne, Germany.
Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems.
View Article and Find Full Text PDFToxicol Appl Pharmacol
November 2014
Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan. Electronic address:
Fingolimod, a sphingosine 1-phosphate (S1P) receptor subtype 1, 3, 4 and 5 modulator, has been used for the treatment of patients with relapsing forms of multiple sclerosis, but atrioventricular conduction block and/or QT-interval prolongation have been reported in some patients after the first dose. In this study, we directly compared the electropharmacological profiles of fingolimod with those of siponimod, a modulator of sphingosine 1-phosphate receptor subtype 1 and 5, using in vivo guinea-pig model and in vitro human ether-a-go-go-related gene (hERG) assay to better understand the onset mechanisms of the clinically observed adverse events. Fingolimod (0.
View Article and Find Full Text PDFEur J Clin Pharmacol
March 2014
St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland,
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!